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Abstract
Background: Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is
based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of
radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a
nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this,
177Lu-
DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for
NETs.
Methodology and Findings: DOTATATE was labeled with Lutetium-177 (
177Lu) (labeling efficiency 98%; Rf,0.8).
Polyethylene Glycol (PEG) coated
177Lu-DOTATATE-PLGA NPs (50:50 and 75:25) formulated, were spherical with mean size of
304.5680.8 and 733.46101.3 nm (uncoated) and 303.8667.2 and 494.3671.8 nm (coated) for PLGA(50:50) and PLGA(75:25)
respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50:50 & 75:25)
were assessed and compared. Mean EE was 77.37564.98% & 67.88565.12% (uncoated) and 65.38565.67% & 58.49565.35%
(coated). NPs showed initial burst release between 16.64–21.65% with total 42.83–44.79% over 21days. The release
increased with coating to 20.4–23.95% initially and 60.97–69.12% over 21days. In-vivo studies were done in rats injected
with
177Lu-DOTATATE and
177Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing
rats at different time points over 24 hr post-injection. With
177Lu-DOTATATE, renal uptake of 37.89610.2%ID/g was
observed, which reduced to 4.661.97% and 5.2761.66%ID/g with uncoated and coated
177Lu-DOTATATE-NP. The high liver
uptake with uncoated
177Lu-DOTATATE-NP (13.6863.08% ID/g), reduced to 7.2062.04%ID/g (p=0.02) with PEG coating.
Conclusion: PLGA NPs were easily formulated and modified for desired release properties. PLGA 50:50 NPs were a more
suitable delivery vehicle for
177Lu-DOTATATE than PLGA 75:25 because of higher EE and slower release rate. Reduced renal
retention of
177Lu-DOTATATE and reduced opsonisation strongly advocate the potential of
177Lu-DOTATATE-PLGA-PEG NPs
to reduce radiation dose in PRRT.
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Introduction
Neuroendocrine tumors (NETs) are the tumors arising from
dispersed neuroendocrine cells in the body. They are generally
slow growing and are diagnosed at a very later stage when they
have already metastasized, thus when a radical treatment is no
longer possible [1].
In recent years, Peptide receptor radionuclide therapy (PRRT)
is increasingly employed for the treatment of NETs. It involves the
administration of radiolabeled somatostatin analogues, taking
advantage of the over-expression of Somatostatin Receptors
(SSTRs) on NETs. Various types of somatostatin analogues, such
as octreotide, lanreotide and octreotate are currently available.
These analogues have been successfully labeled with various
diagnostic and therapeutic radionuclides such as Ga-68, In-111,
Y-90 and Lu-177. The introduction of the bifunctional metal
chelator Tetraazacyclododecane tetra acetic acid (DOTA) has
considerably improved the stability of somatostatin radioconju-
gates and made it possible to use a variety of radiation, for PRRT.
A major limitation of PRRT, which dampens its therapeutic
potential, is the associated nephrotoxicity due to high uptake and
retention of radiolabeled somatostatin receptors. Renal uptake and
retention of radiolabeled SSTRs is because of two reasons: Their
active reabsorption in PCT by receptor-mediated endocytosis,
probably involving megalin or cubilin and the expression of
SSTRs normally in kidneys [2].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34019Depending on the target tissue, biodistribution profile and route
of excretion, different radionuclide therapies have different critical
organs that limit the dose of therapeutic radionuclide. Bone
marrow is the common critical organ for most radionuclide
therapies and gets a significant radiation dose in PRRT as well but
it the kidney that is the dose-limiting organ. To reduce radiation
exposure to the kidney, co-infusion of a mixture of arginine and
lysine with radiolabeled somatostatin analogues is being practiced.
But these strategies are associated with some disadvantages,
mainly their hyper-osmolarity and their tendency to cause
vomiting and metabolic changes [3].
Apart from this, SSTRs are expressed in a number of normal
organs including Brain, GI tract, pancreas, liver, spleen, adrenals
and pituitary grand resulting in their unnecessary radiation
exposure during PRRT [4]. The tumor response rate is variable
and depends on multiple factors such as: type of radiolabeled
somatostatin, tumor type, tumor burden and tumor size. Various
dose regimes have been practiced and reported. However, no
particular protocol/consensus has been laid in any of the nuclear
medicine society guidelines, so far. New ways, thus, need to be
explored to overcome the limitations of PRRT.
Latest cancer research is focusing on molecular level to target
tumors for both diagnosis and therapy. Among various approach-
es, the use of nanoparticles in cancer medicine has gained
significant momentum over the past few years. Various drug
delivery and drug targeting systems are currently applied or under
development such as synthetic polymers, microcapsules, lipo-
somes, dendrimers etc. Nanoparticle drug delivery can overcome
the challenges faced by current cancer therapies by increasing
drug bioavailability and accumulation at the pathological site
thereby reducing systemic side effects and multi-drug resistance
[5].
Nano-carriers are used not only in cancer therapy but are also
being increasingly used in detecting cancer at an early stage. US
FDA has even approved two therapeutic nanocarriers: liposomes
and albumin nanoparticles for clinical practices [6].
Although nanoparticles are gaining popularity as drug delivery
vehicles for various chemotherapeutic drugs to reduce their side
effects, not many studies have reported their use for delivering
radiopharmaceuticals. We have tried to develop nanoparticles
based delivery system to deliver PRRT drugs to NETs and
explored its potential to reduce the nephrotoxicity and thus
enhance its efficacy.
The side effects of PRRT might decrease by employing a
nanocarrier to deliver the PRRT drug specifically to the tumor.
Based on this,
177Lu-DOTATATE loaded Poly(DL-Lactide-co-
Glycolide) (PLGA) nanoparticles are formulated in the present
study, as a potential therapeutic model for NETs. The
nanoparticles are characterized for size and shape and their
drug-loading efficiency and in-vitro release kinetics have been
assessed.
177Lu-DOTATATE was chosen as the model drug because of
the favorable radiation characteristics of Lutetium-177 (
177Lu;
bmax=497 keV; c=208 keV (11%) and 113 keV (6.4%)). Also,
PRRT with
177Lu-DOTATATE is being commonly used as a
therapeutic tool against NETs, because of the high affinity of
DOTATATE towards SSTR 2 that is most commonly expressed
SSTR of all.
PLGA was chosen because of its biocompatible and biodegrad-
able nature. It is being widely used in biomedical applications as a
carrier for various drugs. PLGA is available in different
compositions with varying ratio of its constituent monomers,
lactic acid and glycolic acid (L:G ratio). Two most commonly used
forms PLGA 50:50 and 75:25 were used and their characteristics
were compared to evaluate which one of the two is a more suitable
delivery vehicle for
177Lu-DOTATATE.
Materials and Methods
Materials
DOTATATE was procured from ABX. Poly(DL-Lactide-co-
Glycolide) 75:25 and 50:50 (PLGA; 90,000–126,000 g/mol and
40,000–75,000 g/mol), Poly(vinyl alcohol) (PVA; 30,000–
70,000 g/mol) and Poly-ethylene glycol (PEG; 5000) were
procured from Sigma-Aldrich, India. Lutetium-177 (
177Lu), as
Lutetium Chloride (
177LuCl3), was supplied from BRIT (BARC).
Dichloromethane (DCM) and all other reagents were of analytical
grade.
Radiolabeling of DOTATATE
Radiolabeling of DOTATATE with
177Lu was carried out by
the method described by Das et al [7]. Briefly, a stock solution of
DOTATATE was prepared by dissolving it in HPLC grade water
with a concentration of 1 mg/ml. From the specific activity of
177LuCl3, Number of
177Lu moles were calculated and DOTA-
TATE solution was added to 0.1M ammonium acetate buffer of
pH 5 containing Gentisic Acid (40 mg/ml) such that the molar
ratio [Lu]:[DOTATATE]=1:4 and volume of buffer was three
time that of
177LuCl3 and DOTATATE. The reaction mixture
was incubated at 80uC for 1 h after adjusting the pH to 4.5–5. The
final product was filtered using a 0.22 mm Millipore filter. The
entire radiolabeling procedure was carried out under sterile
condition.
The labeling efficiency was determined by Instant Thin layer
chromatography (ITLC) technique using ITLC paper and 50%
aqueous Acetonitrile solution as the solvent.
177Lu-DOTATATE
and
177LuCl3 were spotted on 2 separate strips. The strips were cut
in segments and each segment was counted in a Gamma well
counter (Biodex, Atomlab 950) in
177Lu energy window
(208 keV615%). The stability of the labeled compound was
checked by repeating chromatography at regular time intervals till
6 days after labeling.
Preparation of Blank Nanospheres
Blank PLGA 50:50 or 75:25 nanoparticles were prepared using
double emulsion solvent evaporation technique with some
modifications [8]. The oil phase (o) was prepared by dissolving
50 mg PLGA 50:50 or PLGA 75:25 in 3 ml Dichloromethane
(DCM). Primary emulsion, (w1/o), was formed by mixing the oil
phase with 0.5 ml of HPLC grade water (w1), followed by
homogenization at 20,000 rpm for 3 min. To the primary
emulsion 10 ml of aqueous solution of PVA (14% w/v) was added
(w2) and homogenized for 4–5 min at 20,000 rpm to form
secondary emulsion (w1/o/w2). Emulsion was stirred using
magnetic stirrer (400 rpm) at room temperature for 3 h to
evaporate DCM. Nanospheres were collected by centrifugation
at 19,000 rpm for 30 min and washed twice with water.
Coating of Nanospheres
To reduce opsonisation, the pre-formulated blank PLGA 50:50
or 75:25 nanoparticles were coated with Polyethylene Glycol
(PEG) by incubating them in 10% aqueous solution of PEG (w/v)
overnight. The coated particles were recovered by centrifugation
at 8,000–10,000 rpm for 10 min.
Characterization of Nanospheres
The nanoparticles were characterized for shape and size by
electron microscope. The surface morphology was assessed by
PLGA Nanoparticles for PRRT
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15–25 kV) by air-drying followed by gold coating of the stub.
The shape and size was determined by Transmission electron
microscope (TEM, Morgagni 268D; FEI Inc.; operated at 40–
100 kV) by negative staining. A drop of nanoparticles suspension
mixed thoroughly with a drop of 1% (w/v) Phosphotungustic acid
(PTA) was placed on a carbon film coated on a grid. Excess
solution was drained off; grid was dried and observed under TEM.
Size analysis was done using Soft Image System (SIS) image
processing software.
The size analysis of uncoated and PEG-coated PLGA
nanoparticles was also done using Particle Size Analyzer
(DelsaNanoC Particle size Analyzer; Laser diode, 658 nm,
30 mW; Beckman Coulter Inc.)
Encapsulation of
177Lu-DOTATATE in nanospheres
177Lu-DOTATATE was encapsulated in pre-formulated blank
PLGA 50:50 or 75:25 nanoparticles by incubating with
177Lu-
DOTATATE overnight (4 mg/ml) at 37uC. The particles were
then centrifuged at 8000–10,000 rpm for 10 min at 4uC [6,9–11].
For coating of loaded nanoparticles, the pre-formulated blank
nanoparticles were incubated with
177Lu-DOTATATE (4 mg/ml)
at 37uC. After 4 h of incubation 10% PEG solution was added to it
and incubated overnight at 37uC. The particles were then
centrifuged at 8000–10,000 rpm for 10 min at 4uC.
Amount of
177Lu-DOTATATE encapsulated in nanoparticles is
represented as a percentage of the total activity added and
calculated by counting the activity in the supernatant in Gamma
Well Counter in
177Lu energy window (208 keV615%).
%E~ At{As ðÞ =At ½  |100
Where,
%E=Encapsulation Efficiency
At=Total activity added
As=Activity in supernatant
1 mCi of
177Lu was prepared by serial dilution method and used
as standard. Appropriate decay corrections were applied, wher-
ever required.
In-Vitro Release Kinetics
For In-vitro release kinetics, the pellet of the PLGA 50:50 or
75:25 nanoparticle samples obtained after centrifugation, were
suspended in Phosphate Buffered Saline (PBS, pH 7.4). The
samples were fixed horizontally with constant and slow stirring
(400 rpm) at 37uC. The supernatant was withdrawn from each
sample at regular time intervals till 21days (that is, 3 half-lives of
177Lu) after centrifugation at 8000–10,000 rpm for 10 min and
replaced by fresh medium. The supernatant samples were counted
in Gamma Well Counter in
177Lu energy window
(208 keV615%).
Similar to encapsulation studies, 1 mCi of
177Lu was prepared
by serial dilution method and used as standard. Appropriate decay
corrections were applied, wherever required.
Same procedure was followed to assess the release kinetics of
PEG-coated PLGA particles.
All the experiments were done in triplicates.
In vivo Biodistribution Studies
Biodistribution of
177Lu-DOTATATE-PLGA (both uncoated
and PEG coated) was observed in normal wistar albino rats (150–
200 g), obtained from institutional central animal facility. Ethical
clearance was obtained from Institutional Animal Ethics Com-
mittee (IAEC) for animal experiments. The uptake was compared
with that of
177Lu-DOTATATE.
The rats were divided in three groups – A, B and C. Group A
was injected
177Lu-DOTATATE, B was injected
177Lu-DOTA-
TATE-PLGA nanoparticles (uncoated) and C was injected
177Lu-
DOTATATE-PLGA-PEG nanoparticles. Number of rats (n) was
18. Around 200 mCi of radioactivity was injected via tail vein and
images were acquired at 1, 2, 4, 6, 12 and 24 h post-injection
(n=3 per time point per group) on Dual head Gamma-camera
(Symbia by Siemens).
After imaging the rats were sacrificed with intra-peritoneal
injection of pentobarbitone (60 mg/kg). Blood samples were
collected from heart and organs (Lung, liver, spleen, kidneys,
gut, Bladder, Femur bone) were removed and washed. The organs
were weighed and counted in a Gamma-well counter in
177Lu
energy window (208 keV615%) and percentage injected dose per
gram of organ (%ID/g) was calculated.
1 mCi
177Lu standard was prepared by dilution method and
appropriate decay corrections were applied to all the samples
Statistics
The size of nanoparticles; encapsulation efficiency; percentage
release kinetics and organ uptake values are expressed as mean 6
Figure 1. Chromatograph of
177LuCl3 and
177Lu-DOTATATE in 50% Aqueous Acetonitrile (a); Stability of Labeled compound till 6
th
day post-labeling (b).
doi:10.1371/journal.pone.0034019.g001
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encapsulation efficiencies and release kinetics of PLGA 50:50 and
75:25 and organ uptake of the three groups, one-way ANOVA test
and t test were applied, as and when required. p value of less that
0.05 was considered significant.
Results
Radiolabelling of DOTATATE
The labeling efficiency of
177Lu-DOTATATE, as determined
by Instant Thin layer chromatography (ITLC) technique, was
calculated to be 98% with an Rf value of around 0.8 while the
unlabeled
177LuCl3 remained at the origin (Figure 1(a)). The
radiolabeled compound was stable, with a labeling efficiency of
95.4% on 6
th day (Figure 1(b)).
Morphology and Characterization of Nanospheres
As seen under Scanning Electron Microscope (SEM), the
nanospheres for both the polymers, PLGA 50:50 and PLGA
75:25, were spherical in shape with smooth surfaces (Figure 2).
Figure 2. SEM image showing morphology; and Size analysis using measurement software on TEM Image and Particle size analyzer
for PLGA 50:50 nanoparticles (a), (b) & (c) and PLGA 75:25 nanoparticles (d), (e) & (f) respectively.
doi:10.1371/journal.pone.0034019.g002
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determined by processing software of Transmission electron micro-
scope (TEM) and Particlesizeanalyzer, was around 304.5680.8 nm
with Polydispersity Index (PDI) of 0.190 (Figure 2). PLGA 75:25
nanospheres, on the other hand, were larger in size with a mean
diameter of 733.46101.3 nm and PDI 0.252 (Figure 2).
Coating of Nanospheres
The surface morphology of the PEG-coated PLGA nanospheres
was similar to the uncoated PLGA particles as can be seen in SEM
(Figure 3). The particles were spherical and smooth. The mean
size of PEG-coated PLGA 50:50 particles was 303.8667.2 nm
and PDI was 0.111 (Figure 3). The mean size of PEG-coated
PLGA 75:25 particles was 494.3671.8 nm and PDI was 0.267
(Figure 3). Table 1 sums up the sizes of all the formulations of
PLGA nanospheres.
Encapsulation of
177Lu-DOTATATE in nanospheres
In our study, the percentage encapsulation of
177Lu-DOTATATE
in PLGA 50:50 nanospheres was calculated to be 77.37564.98%
and that in PLGA 75:25 nanospheres 67.88565.12% (Table 2).
The percentage encapsulation in PEG-coated nanospheres was
65.38565.67% and 58.49565.35% for PLGA 50:50 and PLGA
75:25 nanospheres, respectively (Table 2). p value for difference in
encapsulation efficiencies of PEG coated PLGA 50:50 and 75:25
nanospheres was 0.002.
In-Vitro Release Kinetics
The in vitro release profiles of
177Lu-DOTATATE were
obtained by representing the percentage of
177Lu-DOTATATE
release with respect to the amount
177Lu-DOTATATE encapsu-
lated.
Figure 3. SEM image and particle size distribution of PEG-coated (a) & (b) PLGA 50:50 and (c) & (d) PLGA 75:25 Nan particles.
doi:10.1371/journal.pone.0034019.g003
Table 1. Mean Particle Size of Nanospheres.
Mean Size (nm) ± SD PDI
S.No. Nanospheres Without Coating With Coating Without Coating With Coating
1. PLGA 50:50 304.5680.8 303.8667.2 0.190 0.111
2. PLGA 75:25 733.46101.3 494.3671.8 0.252 0.267
SD – Standard Deviation; PDI – Poly-dispersity index.
doi:10.1371/journal.pone.0034019.t001
PLGA Nanoparticles for PRRT
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release in first 5 min between 16.64–21.65%. This burst release
was slightly higher for PEG coated particles; that is; 20.4–23.95%.
This burst release is associated with the drug molecules close to the
nanoparticle surface, which rapidly diffuse on coming in contact
with the medium.
In the first 2 h, the mean cumulative drug release from
uncoated particles was 18.3163.42% and 24.7164.1% (p
value=0.001) while for coated particles was 23.9562.96%
and 29.3665.01% (p value=0.02) for PLGA 50:50 and
PLGA 75:25, respectively (Figure 4).
Following this, a sustained release of drug was observed till
21days that is attributed to matrix erosion.
In PLGA 50:50 nanoparticles, around 1963.06% of drug
was released over first week, 1764.98% over second week
and 963.33% over third week resulting in the cumulative
release of 42.8366.98% of drug over 21days. However,
PLGA 75:25 particles showed a cumulative release of
44.7967.5% drug over 21days with around 2565.84%,
1063.65% and 1163.19% release in first, second and third
weeks respectively.
In comparison to uncoated particles, PEG-coated particles
showed an overall higher drug release. For PEG-coated
PLGA 50:50, the cumulative release over 21days was
observed to be 60.9768.63% while that for PEG-coated
PLGA 75:25 was 69.1269.6% (Figure 5(c)). p value was
calculated to be 0.021.
Since we are aiming a reduction in nephrotoxicity, initial release
of
177Lu-DOTATATE is of more concern that is the time period
the nanoparticles will circulate in blood before accumulating in the
tumor. From these results, it is evident that both the initial and
cumulative release of
177Lu-DOTATATE is higher from PEG-
PLGA 50:50 nanospheres than PLGA 75:25 nanospheres.
In vivo Biodistribution Studies
Figure 5 shows the whole body distribution of radioactivity in
Group A, B and C over 24 h p.i., respectively. In rats injected with
177Lu-DOTATATE (Group A), maximum uptake was seen in
kidneys throughout 24 h. The initial renal uptake at 1 h p.i. was
5469.5%ID/g. Although there was gradual reduction in renal
activity thereafter, 40.9767.98%ID/g and 37.89610.2%ID/g of
activity was retained in kidneys till 4 h and 24 h p.i., respectively
(Figure 5). On the other hand, the renal uptake of group B and
group C was 9.8763.21%ID/g at 4 h, 4.661.97%ID/g at 24 h (p
value=0.001) p.i. and 10.9462.56% at 4 h, 5.2761.66%ID/g at
24 h (p value=0.001) p.i., respectively.
Group B showed highest uptake in liver, that is,
23.7463.33%ID/g at 4 h and 13.6863.08%ID/g at 24 h p.i.
However, liver uptake reduced significantly with PEG coating in
Group C to 15.4162.61%ID/g at 4 h and 7.2062.04%ID/g at
24 h (p value=0.02). Liver activity in Group A at 24 h p.i. was
5.4361.58%ID/g which is comparable to that of group C (p
value=0.13). The comparative distribution of radioactivity in
kidney and liver in three groups of rats is shown in figure 6.
Uptake in spleen for Group A, B and C were 4.9161.74%,
7.8762.83% and 5.9661.92% ID/g at 24 h p.i. The difference in
spleen uptake in Group A and B was significant with a p value of
0.01 whereas the difference was not significant in Group A and C
(p value=0.4).
Group B also showed skeletal uptake of 10.1163.1%ID/g at
24 h p.i., which in group A and C was 3.5461.09% and
3.1661.79%ID/g respectively.
Figures 7 and 8 are the gamma camera images of the three
groups of rats acquired at 4 and 24 h p.i.
Discussion
The radiolabelling of DOTATATE with
177Lu was done by the
method reported by Das et al [7] and a good labeling yield of 98%
could be achieved. The radiolabeled product was found to be
stable.
Our choice of Poly(DL-Lactide-co-Glycolide) (PLGA) as a drug
carrier was governed by the ease of formulation and its excellent
Table 2. Mean Percentage Encapsulation of
177Lu-DOTATATE
in Nanospheres.
Mean %
Encapsulation ± SD
S.No. Nanospheres Without Coating With Coating
1. PLGA 50:50 77.37564.98 65.38565.67
2. PLGA 75:25 67.88565.12 58.49565.35
doi:10.1371/journal.pone.0034019.t002
Figure 4. Cumulative percentage release
177Lu-DOTATATE from uncoated and PEG-coated (a) PLGA 50:50 nanoparticles and (b)
PLGA 75:25 nanoparticles. The bars represent standard deviation. (c) Total release over 21days.
doi:10.1371/journal.pone.0034019.g004
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PLGA has been approved by US FDA for drug delivery use [12].
The nanoparticles formulated by double emulsion solvent
evaporation technique were smooth and spherical in shape as
seen under Scanning electron microscope (SEM) (Figure 2).
The heterogeneity in particle size (Figure 2) is pertaining to the
homogenization method [13]. The concentration of PVA and the
speed of homogenization have been reported to affect the particle
size of PLGA nanoparticles [13–15]. PVA acts to stabilize the
particle droplets [8,13]. While some studies have reported a
decrease in PLGA nanoparticle size and Polydispersity Index
(PDI) with increase in PVA concentration [8,14]; a few others
have reported the reverse trend [15]. In a study, Budhian et al
have reported that as the PVA concentration is increased, the
mean diameter of nanoparticles first decreases and then gradually
increases. The decrease in size is due to enhanced interfacial
stabilization and the increase is due to increased viscosity of the
aqueous phase which in-turn reduces the net shear stress available
for droplet breakdown. This effect is even more prominent in
homogenization method of nanoparticle formulation [13]. Also,
increasing the speed of homogenization also decreases the particle
size [8,15,16]. The PVA concentration (14% w/v) and the
homogenization speed (20,000 rpm) used in the present study were
in light of these factors.
The particle size of PLGA 75:25 nanoparticles was larger as
compared to PLGA 50:50 nanoparticles which may be explained
by the higher molecular weight of PLGA 75:25 (90–12 kDa) than
that of PLGA 50:50 (40–75 kDa) used in the study. The increase
in molecular weight increases the viscosity of the organic phase
reducing the net shear stress for droplet breakdown causing an
increase in the size of nanoparticles [13].
The result of particles size measurements obtained by TEM
software was validated by particle size analyzer. The values
obtained with particle size analyzer were taken into account for
further studies and evaluation pertaining to its greater accuracy
and the potential user dependent errors involved in TEM size
measurement software.
To reduce the uptake of nanoparticles by the Reticulo-
endotheliual system (RES) of the body the nanoparticles were
coated with Poly-ethylene glycol (PEG). The nanoparticles, as
such, are recognized as foreign by the RES of the body when
introduced parenterally or intravenously into the body and hence
are rapidly acted upon by the macrophages for their fast removal
from the blood and in consequence from the body. This process is
termed as Opsonisation. A number of factors contribute in
determining the fate of nanoparticles in-vivo; the most important
ones being the surface properties of nanoparticles, that is, surface
hydrophobicity and surface charge, apart from the particle size.
High hydrophobic surface, low surface charge and large particle
size promote the opsonisation process [6]. For effective drug
targeting by the nanoparticles, it is highly desirable to have a
longer blood circulation time allowing the nanoparticles to
concentrate in the tumor. Various methods have been employed
by different groups for surface modification of nanoparticles. The
most widely used method is the use of PEG on nanoparticle
surface either by coating or chemical conjugation [6,17–19]. PEG
coating makes the nanoparticle less hydrophobic and also
decreases the surface charge that help in evading RES [6,19].
Figure 5. Distribution of
177Lu-DOTATATE (Group A);
177Lu-DOTATATE-PLGA nanoparticles (Group B); and
177Lu-DOTATATE-PLGA-
PEG nanoparticles (Group C) in different organs over 24 h. The bars represent standard deviation.
doi:10.1371/journal.pone.0034019.g005
PLGA Nanoparticles for PRRT
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34019The results indicate a decrease in particle size with PEG coating
as compared to uncoated nanoparticles (Figure 3). PLGA particles
show aggregation that increases with smaller sized particles,
duration of storage and the temperature of storage [20]. Presence
of PEG on the surface of nanoparticles can reduce aggregation as
well as the interfacial tension between the emulsion and the outer
phase by reducing the surface charge and hence the particle size
[21]. TEM images of PEG coated PLGA nanoparticles show
reduced aggregation as compared to the uncoated PLGA
nanoparticles (Figure 9). Nakano et al have reported similar
results with PEGylated PLGA nanospheres and have shown a
decrease in PEGylated nanoparticle size with increase in the
molecular weight and the concentration of PEG used [21].
In the process of encapsulation of drug by after-loading method,
some amount of drug is adsorbed on the surface of nanoparticles
and some amount diffuses inside the particle cavity [22]. A
number of factor have been reported to affect the encapsulation
efficiency of drug in PLGA nanoparticles including: Polymer
nature; Ratio of Lactic acid to Glycolic acid of PLGA (L : G ratio);
Lipophilicity of the drug; Polymer-Drug interaction; pH of the
buffer containing drug and solid state drug-polymer solubility
[12,13,23–26].
In our study, PLGA 75:25 showed lower encapsulation
efficiency than PLGA 50:50, with a p value of 0.002 that is
significant. A possible explanation to this trend might be the
difference in the lipophilicilty of PLGA 75:25 and the drug
resulting in reduced drug-polymer interaction. Since Lactic acid is
more hydrophobic (or lipophilic) that Glycolic acid, as the L:G
ratio of PLGA increases it becomes more lipophilic [12,13,24–26].
On the other hand,
177Lu-DOTATATE is more hydrophilic
[27,28]. This difference results in decreased solid state drug-
polymer solubility, decreased interaction of
177Lu-DOTATATE
with PLGA 75:25 than PLGA 50:50 and hence decreased
encapsulation efficiency.
A decrease in encapsulation efficiency of more hydrophilic
drugs with PEG coating of nanoparticles has also been reported
previously by Ping Li et al [29]. This could be because the drug
molecules close to PEG layer on PLGA nanoparticles surface are
washed off rapidly owing to the water-soluble nature of PEG.
The release of drug from nanoparticles occurs in two phases: an
initial burst release and subsequent sustained release and involves
two different mechanisms: Diffusion and Polymer matrix degra-
dation [8,30].
The in-vitro release kinetics indicates a higher drug-release rate
with PLGA 75:25 nanoparticles in comparison to PLGA 50:50
nanoparticles (p value 0.021) and also with PEG-coated particles
than with uncoated particles. The difference in 2 hour release of
uncoated and PEG coated PLGA 50:50 nanospheres and that of
PLGA 75:25 nanospheres was significant with p values of 0.001
and 0.02 respectively. The difference in overall release from PEG
coated PLGA 50:50 and 75:25 nanospheres was also significant
with a p value of 0.021, although our primary concern is the initial
release of
177Lu-DOTATATE in the first 2–3 hours. As described
above,
177Lu-DOTATATE seems to have less affinity for PLGA
Figure 6. Comparative distribution of radioactivity in (a) kidney and (b) liver of three groups of rats.
doi:10.1371/journal.pone.0034019.g006
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Figure 8. Images of rats acquired at 24 h post-injection. A=Anterior, P=Posterior.
doi:10.1371/journal.pone.0034019.g008
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release [12,13,24–26]. Also, it is possible that some drug molecules
got inserted in the PEG chains on the surface of PLGA
nanoparticles given the hydrophilic nature of both PEG and
177Lu-DOTATATE. Since PEG dissolves at a faster rate, the burst
and the net release are increased [8,29].
Because of PLGA 50:50 nanospheres showed more favorable
release kinetics for
177Lu-DOTATATE that PLGA 75:25, in vivo
studies were done with PLGA 50: 50 nanospheres. Rats injected
with
177Lu-DOTATATE showed radioactive uptake in kidneys,
liver, spleen and gut. Because of renal route of excretion, kidneys
showed highest uptake and retention of
177Lu-DOTATATE and
this also explains bladder activity. By using
177Lu-DOTATATE-
PLGA nanospheres, renal uptake and retention was significantly
reduced with a p value of 0.0001.
However, with
177Lu-DOTATATE-PLGA nanospheres, a high
uptake in liver and spleen was seen. This indicates that RES is the
main route of clearance for
177Lu-DOTATATE-PLGA nano-
spheres. Various in vivo studies have shown RES as the primary
route of clearance for nanoparticles [31,32].
177Lu-DOTATATE-
PLGA nanospheres were also taken up by skeletal system. This
might be because of inhomogeneity in particles size of uncoated
PLGA nanospheres, of which the smaller sized particles were
spontaneously taken up by skeletal system.
PEG coated particles were more homogenous due to which
skeletal uptake of
177Lu-DOTATATE-PLGA-PEG nanospheres
was comparable to that of
177Lu-DOTATATE. PEG coating also
decreased liver uptake (p value 0.02) as compared to uncoated
nanospheres.
177Lu-DOTATATE-PLGA-PEG nanospheres not
only reduced renal uptake but also RES uptake. Reduction of RES
uptake by PEG coating is also shown by Goldie Kaul et al with
PEG modified gelatin nanoparticles in subcutaneous murine
tumors model [33]. In another in vitro study, Jin Xie et al have
shown reduced uptake of Fe3O4 nanoparticles by macrophages
after PEGylation and concluded that PEG coated particles can
escape RES [34].
Reduction in renal uptake and retention strongly supports that
using PEG coated PLGA 50:50 nanospheres as a carrier for
177Lu-
DOTATATE, can reduce nephrotoxicity and unnecessary
radiation dose to other normal organs.
Conclusion
The study is intended to develop a suitable delivery vehicle for
PRRT drugs for therapy of NETs. The results suggest that
PLGA nanoparticles are suitable for the purpose owing to their
ease of formulation and easy surface modification for desired
release rate. Among the two forms of PLGA, PLGA 50:50
nanospheres are a more preferable delivery vehicle of
177Lu-
DOTATATE because of its higher encapsulation efficiency and
sustained release characteristics as compared to that of PLGA
75:25 nanospheres. In vivo studies showing reduced renal uptake
also advocate the potential of PEG coated
177Lu-DOTATATE-
PLGA 50:50 nanospheres towards achieving reduction in
nephrotoxicity and unnecessary radiation dose to normal tissues,
associated with PRRT and simultaneously increasing its efficacy
by enhancing the drug bioavailability. To our knowledge of
literature, this is the first study reporting the application of
nanoparticles in PRRT and the results encourage further
research into development of drug delivery systems for PRRT
drugs.
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